{"DataElement":{"publicId":"4787968","version":"1","preferredName":"Minimal Residual Disease (MRD) Day 8 Induction Therapy Blood Sensitivity Value","preferredDefinition":"Sensitivity of Minimum residual disease status by flow cytometry, in blood, day 8.","longName":"4778983v1.0:4787953v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"4778983","version":"1","preferredName":"Minimal Residual Disease Day 8 Induction Therapy Blood Sensitivity","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy._The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours._A number with no fractional part.::8_Treatment designed to be used as a first step toward shrinking the cancer and in evaluating response to drugs and other agents. Induction therapy is followed by additional therapy to eliminate whatever cancer remains._A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood._The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"2452232v1.0:4778981v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2452232","version":"1","preferredName":"Minimal Residual Disease","preferredDefinition":"remainder of a tumor or a neoplasm/cancer after primary, potentially curative therapy.","longName":"C3896","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Measurable Residual Disease","conceptCode":"C3896","definition":"Evidence for remaining tumor following primary treatment that is only apparent using highly sensitive techniques.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D052842-7AD9-4FD3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-22","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-22","modifiedBy":"ONEDATA","dateModified":"2006-02-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"4778981","version":"1","preferredName":"Day Integer::8 Neoadjuvant Therapy Blood Sensitivity","preferredDefinition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.:A number with no fractional part, including the negative and positive numbers as well as zero.::8:Treatment given as a first step to shrink a tumor before the main treatment, which is usually surgery, is given. Examples of neoadjuvant therapy include chemotherapy, radiation therapy, and hormone therapy. It is a type of induction therapy. :A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.:The ability to respond to physical stimuli or to register small physical amounts or differences.","longName":"4778981v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Day","conceptCode":"C25301","definition":"The time for Earth to make a complete rotation on its axis; ordinarily divided into twenty-four hours, equal to 86 400 seconds. This also refers to a specific day.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Neoadjuvant Therapy","conceptCode":"C15665","definition":"Therapy administered prior to the primary treatment for the purpose of making the primary treatment more effective.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Blood","conceptCode":"C12434","definition":"A liquid tissue; its major function is to transport oxygen throughout the body. It also supplies the tissues with nutrients, removes waste products, and contains various components of the immune system defending the body against infection. Several hormones also travel in the blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Sensitivity","conceptCode":"C25201","definition":"The ability to respond to physical stimuli or to register small physical amounts or differences.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1315538F-5179-B2BC-E050-BB89AD430341","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-06","modifiedBy":"ONEDATA","dateModified":"2015-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008563","version":"1","preferredName":"Therapy Results","preferredDefinition":"the results or effects (does not include CTC Adverse Events) of therapeutic agents or procedures administered to the patient.","longName":"TX_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6690D31-4081-494A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-01-06","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-02-11","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1315538F-518A-B2BC-E050-BB89AD430341","latestVersionIndicator":"Yes","beginDate":"2015-04-06","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Created for TARGET harmonization project. mc 4/6/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4787953","version":"1","preferredName":"MRD Sensitivity Percent Value","preferredDefinition":"Numerical representation of the sensitivity of the minimum residual disease during induction therapy.","longName":"4787953v1.0","context":"NCIP","contextVersion":"1","type":"Non-enumerated","dataType":"NUMBER","unitOfMeasure":"%","minLength":null,"maxLength":"4","minValue":null,"maxValue":null,"decimalPlace":"2","PermissibleValues":[],"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2414933","version":"1","preferredName":"Value","preferredDefinition":"A numerical quantity measured or assigned or computed.","longName":"C25712","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Value","conceptCode":"C25712","definition":"A numerical quantity measured or assigned or computed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"02772734-9BE5-6ADF-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-10-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-10-06","modifiedBy":"ONEDATA","dateModified":"2005-10-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D785-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2015-04-28","changeDescription":"Created for TARGET CDE harmonization project. mc 4/10/2015","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650571","version":"1","longName":"ALL","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Sensitivity of Minimum residu","type":"Preferred Question Text","description":"Sensitivity of Minimum residual disease status by flow cytometry, day 8 of induction therapy","url":null,"context":"NCIP"},{"name":"Original TARGET Question Text","type":"Alternate Question Text","description":"Sensitivity of Minimum residual disease status, day 8 of induction therapy","url":null,"context":"NCIP"},{"name":"Typical Data Entry","type":"NOTE","description":"Typical entry will be 0.01% (default) or 0.1%","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"135EEC98-D908-84BF-E050-BB89AD436F63","latestVersionIndicator":"Yes","beginDate":"2015-04-10","endDate":null,"createdBy":"COOPERM","dateCreated":"2015-04-10","modifiedBy":"COOPERM","dateModified":"2017-02-02","changeDescription":"Created for TARGET harmonization project per request by T.Davidsen. mc 4/10/2015 Updated definition and question text per request by Tanja. mc 12/22/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}